Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.729,31
0,37%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immatics NV (IMTX) Immatics NV (IMTX) Notizie

IMTX

Immatics NV (IMTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMTX
DataOraFonteTitoloSimboloCompagnia
14/05/202413:00GlobeNewswire Inc.Immatics Announces First Quarter 2024 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
21/03/202412:00GlobeNewswire Inc.Immatics Announces Full Year 2023 Financial Results and Corporate UpdateNASDAQ:IMTXImmatics NV
22/01/202418:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
19/01/202414:58Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMTXImmatics NV
18/01/202402:30GlobeNewswire Inc.Immatics Announces Pricing of $175 Million Public OfferingNASDAQ:IMTXImmatics NV
17/01/202422:01GlobeNewswire Inc.Immatics Announces Proposed Public OfferingNASDAQ:IMTXImmatics NV
16/01/202410:06PR Newswire (US)DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingNASDAQ:IMTXImmatics NV
30/11/202310:00GlobeNewswire Inc.Levicept Appoints Eliot Forster as CEONASDAQ:IMTXImmatics NV
14/11/202313:00GlobeNewswire Inc.Immatics Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
08/11/202313:00GlobeNewswire Inc.Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialNASDAQ:IMTXImmatics NV
24/10/202313:00GlobeNewswire Inc.Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T MonotherapyNASDAQ:IMTXImmatics NV
14/09/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMTXImmatics NV
13/09/202323:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IMTXImmatics NV
11/09/202313:00GlobeNewswire Inc.Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNASDAQ:IMTXImmatics NV
25/08/202322:11Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:IMTXImmatics NV
17/08/202313:00GlobeNewswire Inc.Immatics Announces Second Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
10/08/202313:00GlobeNewswire Inc.Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid TumorsNASDAQ:IMTXImmatics NV
24/07/202313:00GlobeNewswire Inc.Immatics Announces $35 Million Equity Investment from Bristol Myers SquibbNASDAQ:IMTXImmatics NV
20/06/202322:21Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMTXImmatics NV
16/05/202313:00GlobeNewswire Inc.Immatics Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
02/05/202313:00GlobeNewswire Inc.Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAMENASDAQ:IMTXImmatics NV
01/05/202313:00GlobeNewswire Inc.Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic CollaborationNASDAQ:IMTXImmatics NV
22/03/202311:57Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:IMTXImmatics NV
21/03/202312:31GlobeNewswire Inc.Immatics Announces Full Year 2022 Financial Results and Corporate UpdateNASDAQ:IMTXImmatics NV
14/02/202323:24Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:IMTXImmatics NV
07/02/202312:07Edgar (US Regulatory)Schedule 13g
(sc 13g)		NASDAQ:IMTXImmatics NV
21/11/202205:15TipRanksSVB Securities Sticks to Their Buy Rating for Immatics (IMTX)NASDAQ:IMTXImmatics NV
18/11/202200:15TipRanksChardan Capital Sticks to Their Buy Rating for Immatics (IMTX)NASDAQ:IMTXImmatics NV
17/11/202213:00GlobeNewswire Inc.Immatics Announces Third Quarter 2022 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
11/10/202212:31Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:IMTXImmatics NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMTX

La tua Cronologia

ASX
SXS
TG
M8G
MGI Media and Games Invest
LSE
UB02
Ubsetf Jpngba
EU
I2STS
LS 2STS INAV
NYSE
NEB
New England Business
BOV
K1EY34Q
Keycorp
ASX
YTMIP1
Equity Trustees
TSX
VUN
Vanguard US Total Market...
DBI
G949
XMIUE1C USD iNAV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network